Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingWe manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for protein analysis, automated western blot, and multiplexed ELISA workflows.
In the company’s own words · 10-K filed Aug 22, 2025 · SEC EDGAR
Business segments
Jun 2026 · $321.2MThe company’s own SEC segment disclosure.
- United States$166.1M52%
- EMEA Excluding UK$80.3M25%
- China$26.9M8%
- APAC Excluding Greater China$22.1M7%
- United Kingdom$14.5M5%
- Rest Of World$11.3M4%
Bio-Techne (TECH) reported revenue of $311M in Q3 2026 (quarter ended Mar 31, 2026), down 1.5% from the same quarter a year earlier. That came with a gross margin of 67% and net income of $51M (16% of revenue). For the full year FY2025, revenue was $1.22B (+5.2% year on year) and net income $73M. Its largest region in Jun 2026 was United States at $166M, 52% of the disclosed total, well ahead of EMEA Excluding UK at 25%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
The closest names by size in the same industry